Evaluation of the safety, tolerability, pharmacokinetics and pharmacodynamics of SM17 in healthy volunteers: results from pre-clinical models and a first-in-human, randomized, double blinded clinical trial.

Background: Alarmins mediate type 2 T helper cell (Th2) inflammation and serve as upstream signaling elements in allergic inflammation and autoimmune responses. The alarmin interleukin (IL)-25 binds to a multi-domain receptor consisting of IL-17RA and IL-17RB subunits, resulting in the release of Th2 cytokines IL-4, IL-5, IL-9 and IL-13 to drive an inflammatory response. Therefore, the blockage of IL-17RB via SM17, a novel humanized monoclonal antibody, offers an attractive therapeutic target for Th2-mediated diseases, such as asthma.

Implementation of the Oxygen Saturation Index as a Predictor of Outcome in Prenatally Diagnosed CDH Neonates in the First 24 Hours of Life.

Aims: This study aimed to evaluate the Oxygen Saturation Index (OSI) as a noninvasive measure for early postnatal management and outcome prediction in neonates with congenital diaphragmatic hernia (CDH). Additionally, the study analyzed the correlation and predictive ability of OSI, Oxygenation Index (OI), Horovitz Index (HI), and partial pressure of arterial oxygen (PaO) regarding mortality and the need for extracorporeal membrane oxygenation (ECMO).

Methods: A retrospective, single-center study using data from 2013 to 2020.